Independently of the prior treatment received, only one patient experienced grade 3 treatment-related toxicity.<h4>Conclusions</h4>This case series highlights the clinical heterogeneity and poor prognosis of NSCLC patients with <i>BRAF</i> class II-III mutations. Here, BRAF is linked to non-small cell lung carcinoma.